Atrys Health (ATRY.MC) Stock Price
Atrys Health Price
Revenue has compounded at 45.5% per year over the past 13 years to 141.01 M EUR. Earnings per share have declined at 37.2% per year over the last 6 years. Atrys Health's net margin stands at -71.1%, down from -19.2% several years earlier. Analysts set a median price target of 5.76 EUR, implying 113.0% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 16% above its 52-week low.
Atrys Health stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Atrys Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Atrys Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Atrys Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Atrys Health Price |
|---|---|
| 9/25/2026 | 2.71 EUR |
| 9/24/2026 | 2.76 EUR |
| 9/23/2026 | 2.82 EUR |
| 9/22/2026 | 2.84 EUR |
| 9/21/2026 | 2.83 EUR |
| 9/18/2026 | 2.86 EUR |
| 9/17/2026 | 2.80 EUR |
| 9/16/2026 | 2.85 EUR |
| 9/15/2026 | 2.93 EUR |
| 9/14/2026 | 2.83 EUR |
| 9/11/2026 | 2.70 EUR |
| 9/10/2026 | 2.51 EUR |
| 9/9/2026 | 2.48 EUR |
| 9/8/2026 | 2.47 EUR |
| 9/7/2026 | 2.57 EUR |
| 9/4/2026 | 2.54 EUR |
| 9/3/2026 | 2.49 EUR |
| 9/2/2026 | 2.50 EUR |
| 9/1/2026 | 2.52 EUR |
| 8/31/2026 | 2.53 EUR |
| 8/28/2026 | 2.53 EUR |
| 8/27/2026 | 2.53 EUR |
| 8/26/2026 | 2.56 EUR |
| 8/25/2026 | 2.52 EUR |
| 8/21/2026 | 2.53 EUR |
| 8/20/2026 | 2.55 EUR |
| 8/19/2026 | 2.55 EUR |
| 8/18/2026 | 2.57 EUR |
| 8/17/2026 | 2.60 EUR |
| 8/14/2026 | 2.57 EUR |
Atrys Health Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Atrys Health Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 2.00 | 5.00 | 8.00 | 7.00 | 14.00 | 33.00 | 121.00 | 158.00 | 201.00 | 212.00 | 141.00 | 151.00 | 169.00 | 181.00 | 191.00 |
| – | 100.00 | 150.00 | 60.00 | -12.50 | 100.00 | 135.71 | 266.67 | 30.58 | 27.22 | 5.47 | -33.49 | 7.09 | 11.92 | 7.10 | 5.52 |
| 6,100.00 | 100.00 | 40.00 | 37.50 | 85.71 | 85.71 | 36.36 | 82.64 | 15.19 | 70.15 | 68.40 | 43.26 | 43.26 | 43.26 | 43.26 | 43.26 |
| 61.00 | 2.00 | 2.00 | 3.00 | 6.00 | 12.00 | 12.00 | 100.00 | 24.00 | 141.00 | 145.00 | 61.00 | 65.33 | 73.11 | 78.30 | 82.63 |
| – | – | – | – | – | 1.00 | -3.00 | -15.00 | -6.00 | 2.00 | -10.00 | -9.00 | 26.00 | 32.00 | 38.00 | -18.00 |
| – | – | – | – | – | 7.14 | -9.09 | -12.40 | -3.80 | 1.00 | -4.72 | -6.38 | 17.22 | 18.93 | 20.99 | -9.42 |
| – | 1.00 | – | – | – | – | -5.00 | -23.00 | -23.00 | -45.00 | -31.00 | -100.00 | – | 5.00 | 10.00 | – |
| – | – | – | – | – | – | – | 360.00 | – | 95.65 | -31.11 | 222.58 | – | – | 100.00 | – |
| 75.92 | 75.92 | 10.87 | 10.87 | 21.76 | 25.59 | 31.49 | 61.50 | 75.89 | 75.93 | 75.92 | 75.93 | 75.93 | 75.93 | 75.93 | 75.93 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Atrys Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Atrys Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Atrys Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Atrys Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Atrys Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Atrys Health stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Atrys Health Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Atrys Health business model & stock analysis
Atrys Health SWOT Analysis
Strengths
Atrys Health SA has several strengths that contribute to its success in the healthcare industry. Firstly, the company has a strong reputation for providing high-quality medical services and solutions to its customers. This reputation has been built over time through the company's commitment to excellence and continuous improvement.
Secondly, Atrys Health SA has a well-established network of healthcare professionals and facilities, allowing them to deliver effective and efficient healthcare services to a wide range of patients. This network provides the company with a competitive advantage and enables them to serve a larger customer base.
Additionally, Atrys Health SA has a strong financial position, which allows them to invest in advanced technologies and research and development. This financial stability enables the company to stay ahead of industry trends and provide innovative solutions to its customers.
Weaknesses
Despite its strengths, Atrys Health SA also faces a few weaknesses that need to be addressed. One weakness is the high dependency on a few key healthcare professionals within the company. This dependence creates a potential risk as the loss or unavailability of these professionals may impact the company's ability to deliver services effectively.
Another weakness is the limited geographical presence of Atrys Health SA. While the company has a strong presence in certain regions, expanding into new markets and geographies could be challenging and require significant investment.
Opportunities
Atrys Health SA has several opportunities that it can leverage to further grow and expand its business. One opportunity is the increasing demand for advanced medical technologies and solutions. By investing in research and development, the company can develop innovative products and services that cater to this growing market demand.
Another opportunity lies in strategic partnerships and collaborations with other healthcare organizations. By forming alliances, Atrys Health SA can access new markets, share resources, and expand its customer base, leading to increased revenue and market share.
Threats
In the highly competitive healthcare industry, Atrys Health SA faces several threats that it needs to be mindful of. One major threat is the emergence of new competitors in the market. These competitors may offer similar products and services, potentially eroding Atrys Health SA's market share.
Furthermore, regulatory changes and compliance requirements pose a threat to the company. Adapting to new regulations and ensuring compliance can be both time-consuming and expensive.
Lastly, economic downturns and uncertainties in the global economy can impact the demand for healthcare services, potentially affecting Atrys Health SA's revenue and profitability.
Atrys Health Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Atrys Health historical P/E ratio, EBIT multiple, and P/S ratio
Atrys Health annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Atrys Health's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Atrys Health's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Atrys Health's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Atrys Health shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Atrys Health forecasts and price targets in September 2026
Analyst Price Targets 2026Atrys Health Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 9/10/2026 | -EUR | -0.08EUR | 39.50 MEUR | - | 2026 Q2 |
| 3/31/2026 | -EUR | -1.20EUR | 52.50 MEUR | - | 2026 Q1 |
| 9/22/2025 | -EUR | -0.12EUR | 58.50 MEUR | - | 2025 Q3 |
| 7/31/2024 | -EUR | -0.22EUR | 58.20 MEUR | - | 2024 Q2 |
| 3/26/2024 | -EUR | -0.30EUR | 51.00 MEUR | - | 2024 Q1 |
Atrys Health shareholder structure
| % | Name |
|---|---|
24.84759% | |
6.52725% | |
6.39710% | |
5.43604% | |
5.13570% | |
3.12347% |
Atrys Health Beneficial Ownership Filings (SEC 13D/G)
Atrys Health Executives and Management Board
35 members · 40 % women
Ms. Maria Rosa Gonzalez Sans
Managing Director - Optimization and Improvement · since 2021
15,000.00 EUR
Management
Mr. Alfonso Alba
Partner, Vice President - Genetics
Mr. Jose Maria Huch Ginesta
Chief Financial Officer
Mr. Pedro Salord Betrand
Chief Human Resources Officer
Mr. Luis Duran Vizan
Global Chief Technology Officer
Ms. Encarna Vega
Chief Administrative Officer
Mr. Benjamin Guix
Vice President - Oncology, Medical Director of IMOR
Board of Directors
Mr. Santiago De Torres Sanahuja
Chairman of the Board, Other External Director
Ms. Isabel Lozano Fernandez
Other External Director
Mr. Jaime Cano Fernandez
External Independent Director
Ms. Ana Isabel Lopez Porta
External Proprietary Director
Ms. Miryan Mercedes Gonzalez Durantez
External Independent Director
Mr. Antonio Baselga De La Vega
External Proprietary Director
Atrys Health Supply Chain
Atrys Health Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.86 | — | — |
Frequently asked questions about Atrys Health
The business model of Atrys Health SA revolves around providing advanced medical services and solutions. Atrys is a leading medical technology company that offers specialized diagnostic and therapeutic services, particularly in the fields of oncology, radiology, and molecular medicine. They utilize cutting-edge technology and expertise to deliver accurate diagnoses and personalized treatments to patients. Atrys operates through a network of clinics, laboratories, and telemedicine platforms, ensuring accessibility and quality healthcare solutions. With a focus on precision medicine and innovation, Atrys Health SA aims to improve patient outcomes and contribute to the advancement of the medical field.
Atrys Health SA is primarily active in the healthcare industry.
The main competitors of Atrys Health SA in the market include [Competitor 1], [Competitor 2], and [Competitor 3]. These competitors offer similar products and services, which can create a competitive landscape for Atrys Health SA. However, Atrys Health SA stands out with its unique offerings, such as [mention a unique feature or service]. By maintaining its competitive edge and constantly innovating, Atrys Health SA remains a prominent player in the market, outshining its rivals and ensuring its continued success.
Atrys Health SA is a prominent healthcare company with a rich history and background. Founded in 2008, Atrys Health specializes in medical diagnostic services and telemedicine solutions. With a focus on personalized medicine, the company employs advanced technology and innovative approaches to improve patient care and outcomes. Atrys Health has established a solid reputation in the market by providing high-quality medical services to both public and private institutions. Through strategic partnerships and acquisitions, the company has expanded its operations internationally, becoming a global leader in the field. Atrys Health SA is committed to enhancing healthcare accessibility and efficiency, making significant contributions to the medical industry.
Atrys Health SA, a leading healthcare company, has achieved several significant milestones. It has successfully expanded its reach and offerings, establishing a strong global presence. The company has pioneered advanced medical solutions, leveraging state-of-the-art technology and innovative healthcare practices. Atrys Health SA has consistently focused on delivering excellent patient outcomes, offering personalized diagnostic and treatment services. Its commitment to research and development has led to groundbreaking advancements in areas like molecular diagnostics and telemedicine. With a strong emphasis on collaboration and partnerships, Atrys Health SA continues to revolutionize the healthcare industry, improving access to high-quality medical services worldwide.
Atrys Health SA is primarily present in Spain and several other countries in Europe and Latin America.
Atrys Health SA represents values of excellence, innovation, and patient-centricity. With a dedicated focus on providing advanced medical solutions, Atrys Health combines cutting-edge technology with the expertise of highly skilled professionals. Their corporate philosophy revolves around delivering high-quality healthcare services, improving patient outcomes, and enhancing overall well-being. Atrys Health prioritizes integrity, transparency, and ethical practices in every aspect of their operations. By continuously investing in research and development, Atrys Health aims to revolutionize the healthcare industry and become a global leader in personalized medicine and telemedicine solutions.
Analysts currently set an average price target of 5.81 EUR for the Atrys Health stock (median: 5.76 EUR), implying +114.9 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Atrys Health stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Atrys Health to generate revenue of 151.69 M EUR and earnings per share of 0.01 EUR.
The Atrys Health share (ATRY.MC) is listed on 3 stock exchanges, including: Frankfurt (A2T.F), Madrid (ATRY.MC).
Atrys Health SA is a leading European healthcare company that provides innovative solutions in the field of precision medicine. The company operates in various sectors, including diagnostics, oncology, radiotherapy, and telemedicine. Atrys Health aims to find new ways to improve healthcare by using groundbreaking technology and scientific knowledge. Answer: Atrys Health SA is a leading European healthcare company that provides innovative solutions in the field of precision medicine. The company operates in various sectors, including diagnostics, oncology, radiotherapy, and telemedicine. Atrys Health aims to improve healthcare by using groundbreaking technology and scientific knowledge.
The expected revenue of Atrys Health is 151.69 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Atrys Health is 881,165.40 EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Atrys Health is currently 233.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Atrys Health stock.
The price-to-sales ratio (P/S) of Atrys Health is currently 1.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Atrys Health stock.
The Eulerpool Quality Score for Atrys Health is 2/10.
The ISIN of Atrys Health is ES0105148003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Atrys Health is A2JJ74. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Atrys Health is ATRY.MC. The ticker symbol is used to trade Atrys Health shares on the stock exchange.
Atrys Health paid dividends every year for the past 0 years.
Atrys Health is assigned to the 'Health' sector.
The dividends of Atrys Health are distributed in EUR.
Atrys Health stock
Atrys Health Peer Group
Atrys Health Ticker
Atrys Health FIGI
All fundamentals and in-depth analysis of Atrys Health
Our stock analysis for Atrys Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atrys Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.